<DOC>
	<DOCNO>NCT01015300</DOCNO>
	<brief_summary>Von Hippel-Lindau ( VHL ) disease inherit syndrome manifest variety benign malignant tumor . Hemangioblastomas common lesion associate VHL disease affect 60-84 % patient mean age diagnosis 29 year . Standard treatment disease surgery radiotherapy . No approved systemic therapy yet exist . Patients VHL increase growth factor production , specifically vascular endothelial growth factor ( VEGF ) , result angiogenesis ( growth blood vessel ) . Studies show Bevacizumab inhibits growth VEGF protein block VEGF-driven angiogenesis result stabilization regression hemangioblastomas VHL disease patient . The dose bevacizumab 10 mg/kg every two week 6 month .</brief_summary>
	<brief_title>Bevacizumab ( Avastin ) Unresectable/Recurrent Hemangioblastoma From Von-Hippel-Lindau Disease</brief_title>
	<detailed_description />
	<mesh_term>Von Hippel-Lindau Disease</mesh_term>
	<mesh_term>Hemangioblastoma</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>One CNS hemangioblastomas amendable surgical resection recurrent post resection Confirmed diagnosis vonHippelLindau disease No prior treatment VEGF inhibitor Index hemangioblastomas lesion least 5mm MRI No major bleed event hemangioblastoma within 90 day KPS &gt; equal 60 % Age &gt; equal 18 year Prior treatment VEGF inhibitor Major bleed event hemangioblastoma within 90 day Inability comply study and/or follow procedure Life expectancy le 12 week Current recent ( within 4 week first infusion study ) participation experimental drug study Genentech sponsor bevacizumab cancer study Active malignancy permissible treat physician deems concurrent administration bevacizumab contraindicate patient would able complete parameter protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Hemangioblastoma</keyword>
	<keyword>Von Hippel Lindau</keyword>
	<keyword>VHL</keyword>
	<keyword>lesion</keyword>
	<keyword>EGFR</keyword>
</DOC>